Advertisement
Original article| Volume 113, ISSUE 5, P549-560, May 1989

Enhanced glomerular thromboxane A2 mediates some pathophysiologic effect of platelet-activating factor in rabbit nephrotoxic nephritis: Evidence from biochemical measurements and inhibitor trials

  • Daniela Macconi
    Affiliations
    From the Mario Negri Institute for Pharmacological Research, Bergamo, Italy

    From the Department of Pharmacology, Catholic University School of Medicine, Rome, Italy

    From the National Research Council, Center of Cytopharmacology, University of Milan Milan, Italy
    Search for articles by this author
  • Ariela Benigni
    Affiliations
    From the Mario Negri Institute for Pharmacological Research, Bergamo, Italy

    From the Department of Pharmacology, Catholic University School of Medicine, Rome, Italy

    From the National Research Council, Center of Cytopharmacology, University of Milan Milan, Italy
    Search for articles by this author
  • Marina Morigi
    Affiliations
    From the Mario Negri Institute for Pharmacological Research, Bergamo, Italy

    From the Department of Pharmacology, Catholic University School of Medicine, Rome, Italy

    From the National Research Council, Center of Cytopharmacology, University of Milan Milan, Italy
    Search for articles by this author
  • Angelo Ubiali
    Affiliations
    From the Mario Negri Institute for Pharmacological Research, Bergamo, Italy

    From the Department of Pharmacology, Catholic University School of Medicine, Rome, Italy

    From the National Research Council, Center of Cytopharmacology, University of Milan Milan, Italy
    Search for articles by this author
  • Silvia Orisio
    Affiliations
    From the Mario Negri Institute for Pharmacological Research, Bergamo, Italy

    From the Department of Pharmacology, Catholic University School of Medicine, Rome, Italy

    From the National Research Council, Center of Cytopharmacology, University of Milan Milan, Italy
    Search for articles by this author
  • Manuela Livio
    Affiliations
    From the Mario Negri Institute for Pharmacological Research, Bergamo, Italy

    From the Department of Pharmacology, Catholic University School of Medicine, Rome, Italy

    From the National Research Council, Center of Cytopharmacology, University of Milan Milan, Italy
    Search for articles by this author
  • Norberto Perico
    Affiliations
    From the Mario Negri Institute for Pharmacological Research, Bergamo, Italy

    From the Department of Pharmacology, Catholic University School of Medicine, Rome, Italy

    From the National Research Council, Center of Cytopharmacology, University of Milan Milan, Italy
    Search for articles by this author
  • Tullio Bertani
    Affiliations
    From the Mario Negri Institute for Pharmacological Research, Bergamo, Italy

    From the Department of Pharmacology, Catholic University School of Medicine, Rome, Italy

    From the National Research Council, Center of Cytopharmacology, University of Milan Milan, Italy
    Search for articles by this author
  • Giuseppe Remuzzi
    Correspondence
    Reprint requests: Giuseppe Remuzzi, MD, Mario Negri Institute for Pharmacological Research, Via Gavazzeni, 11, 24100 Bergamo, Italy.
    Affiliations
    From the Mario Negri Institute for Pharmacological Research, Bergamo, Italy

    From the Department of Pharmacology, Catholic University School of Medicine, Rome, Italy

    From the National Research Council, Center of Cytopharmacology, University of Milan Milan, Italy
    Search for articles by this author
  • Carlo Patrono
    Affiliations
    From the Mario Negri Institute for Pharmacological Research, Bergamo, Italy

    From the Department of Pharmacology, Catholic University School of Medicine, Rome, Italy

    From the National Research Council, Center of Cytopharmacology, University of Milan Milan, Italy
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Previous studies have shown that platelet-activating factor (PAF) receptor blocking has a protective effect on rabbit nephrotoxic nephritis (NTN). We examined whether arachidonic acid (AA) metabolism is altered in NTN and whether a PAF receptor antagonist has any influence on such changes. Rabbits injected with anti-glomerular basement membrane antiserum in the heterologous phase had a markedly increased glomerular thromboxane B2 (TxB2) production level, whereas no changes have been detected in glomerular 6-keto-prostaglandin F (6-keto-PGF) and prostaglandin E2 (PGE2). During the autologous phase of the disease, the glomerular TxB2 level was even higher than in the heterologous phase. The level of 6-keto-PGF was significantly lower than normal, and the level of PGE2 was unchanged in respect to the basal values. The use of L-652,731 (a specific PAF receptor antagonist) reversed the abnormal generation of AA metabolites at glomerular level both in the heterologous and autologous phase of the disease. The effect of L-652,731 on AA metabolism is likely to be an indirect result of the PAF receptor blocking, because L-652,731 given to normal rabbits had no direct effect on glomerular AA metabolism. To assess whether the beneficial effect of L-652,731 in NTN is at least in part mediated by its capability of suppressing the excessive intrarenal synthesis of thromboxane A2 (TxA2), we compared the effect of L-652,731 with that of a selective TxA2-synthase inhibitor (FCE-22178). FCE-22178 ameliorated the morphologic expression of rabbit NTN and reduced function deterioration. The protective effect of L-652,731 on proteinuria in the autologous phase and on glomerular filtration rate in both phases was superior to that of FCE-22178. We conclude that an excessive intraglomerular synthesis of TxA2 occurs in rabbit NTN that can play a role in renal function deterioration. Both a specific PAF receptor antagonist and a TxA2-synthase inhibitor reduced the exaggerated TxA2 synthesis and favorably influenced the evolution of the disease.

      Abbreviations:

      AA (arachidonic acid), GBM (glomerular basement membrane), GFR (glomerular filtration rate), KRB (Krebs Ringer phosphate buffer), NTN (nephrotoxic nephritis), NTS (nephrotoxic serum), PAF (platelet-activating factor), PGE2 (prostaglandin E2), PGI2 (prostacyclin (prostaglandin I2)), PRP (platelet-rich plasma), TAC (threshold aggregating concentration), TxA2 (thromboxane A2), TxB2 (thromboxane B2)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pinckard RN
        • McManus LM
        • Hanahan DJ
        Chemistry and biology of acetyl glyceryl ether phosphorylcholine (platelet-activating factor).
        Adv Inflammation Res. 1982; 4: 147-169
        • Camussi G
        • Tetta C
        • Coda R
        • Segoloni GP
        • Vercellone A
        Platelet-activating factor-induced loss of glomerular anionic charges.
        Kidney Int. 1984; 25: 73-81
        • Pirotzky E
        • Page C
        • Morley J
        • Bidault J
        • Benveniste J
        Vascular permeability induced by PAF-acether (platelet-activating factor) in the isolated perfused rat kidney.
        Agents Actions. 1985; 16: 17-18
        • Schiondorff D
        • Goldwasser P
        • Satriano JA
        Synthesis of platelet-activating factor by isolated glomeruli and cultured mesangial cells of rat kidney [Abstract].
        Clin Res. 1985; 33: 588A
        • Schlondorff D
        • Satriano JA
        • Hagege J
        • Perez J
        • Baud L
        Effect of platelet-activating factor and serum-treated zymosan on prostaglandin E2 synthesis, arachidonic acid release, and contraction of cultured rat mesangial cells.
        J Clin Invest. 1984; 73: 1227-1231
        • Ardaillou N
        • Hagege J
        • Nivez M-P
        • Ardaillou R
        • Schlondorff D
        Vasoconstrictor-evoked prostaglandin synthesis in cultured human mesangial cells.
        Am J Physiol. 1985; 248: F240-F246
        • Ito S
        • Camussi G
        • Tetta C
        • Milgrom F
        • Andres G
        Hyperacute renal allograft rejection in the rabbit. The role of platelet-activating factor and of cationic proteins derived from polymorphonuclear leukocytes and from platelets.
        Lab Invest. 1984; 51: 148-161
        • Camussi G
        • Tetta C
        • Deregibus MC
        • Bussolino F
        • Segoloni G
        • Vercellone A
        Platelet-activating factor (PAF) in experimentally-induced rabbit acute serum sickness: role of basophil-derived PAF in immune complex deposition.
        J Immunol. 1982; 128: 86-94
        • Hruby Z
        • Lowry RP
        • Blais D
        Effect of platelet activating factor antagonist CV3988 in an autologous nephrotoxic nephritis model [Abstract].
        Clin Res. 1986; 34: 602a
        • Lianos EA
        • Zanglis A
        • Noble B
        Renal immune injury: glomerular platelet activating factor (PAF) synthesis [Abstract].
        Clin Res. 1987; 35: 551A
        • Haliam TJ
        • Sanchez A
        • Rink TJ
        Stimulus-response coupling in human platelets. Changes evoked by platelet-activating factor in cytoplasmic free calcium monitored with the fluorescent calcium indicator quin 2.
        Biochem J. 1984; 218: 819-827
        • Naccache PH
        • Molski MM
        • Volpi M
        • Becker EL
        • Sha'afi RI
        Unique inhibitory profile of platelet activating factor induced calcium mobilization, polyphosphoinositide turnover and granule enzyme secretion in rabbit neutrophils towards pertussis toxin and phorbol ester.
        Biochem Biophys Res Commun. 1985; 130: 677-684
        • Bussolino F
        • Aglietta M
        • Sanavio F
        • Stacchini A
        • Lauri D
        • Camussi G
        Alkyl-ether phosphoglycerides influence calcium fluxes into human endothelial cells.
        J Immunol. 1985; 135: 2748-2753
        • Kester M
        • Mené P
        • Dubyak GR
        • Dunn MJ
        Elevation of cytosolic free calcium by platelet-activating factor in cultured rat mesangial cells.
        FASEB J. 1987; 1: 215-219
        • Weisman SM
        • Felsen D
        • Vaughan Jr, ED
        Platelet-activating factor is a potent stimulus for renal prostaglandin synthesis: possible significance in unilateral ureteral obstruction.
        J Pharmacol Exp Ther. 1985; 235: 10-15
        • Bertani T
        • Livio M
        • Macconi D
        • et al.
        Platelet activating factor (PAF) as a mediator of injury in nephrotoxic nephritis.
        Kidney Int. 1987; 31: 1248-1256
        • Unanue ER
        • Dixon FJ
        Experimental glomerulonephritis: immunological events and pathogenetic mechanisms.
        Adv Immunol. 1967; 6: 1-90
        • Hwang S-B
        • Lam M-H
        • Biftu T
        • Beattie TR
        • Shen T-Y
        Trans-2,5-Bis-(3,4,5-trimethoxyphenyl) tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor.
        J Biol Chem. 1985; 260: 15639-15645
        • Wu MS
        • Biftu T
        • Doebber TW
        Inhibition of the platelet activating factor (PAF)-induced in vivo responses in rats by trans-2,5-(3,4,5- trimethoxyphenyl) tetrahydrofuran (L-652,731), a PAF receptor antagonist.
        J Pharmacol Exp Ther. 1986; 239: 841-845
        • Lowry OH
        • Rosebrough NF
        • Farr AG
        • Randall RJ
        Protein measurement with the Folin phenol reagent.
        J Biol Chem. 1951; 193: 265-275
        • Born GVR
        • Cross MJ
        The aggregation of blood platelets.
        J Physiol. 1963; 168: 178-195
        • Ciabattoni G
        • Pugliese F
        • Spaldi M
        • Cinotti GA
        • Patrono C
        Radioimmunoassay measurement of prostaglandins E2 and F2 in human urine.
        J Endocrinol Invest. 1979; 2: 173-182
        • Read SM
        • Northcote DH
        Minimization of variation in the response to different proteins of the Coomassie blue G Dye-binding assay for protein.
        Anal Biochem. 1981; 116: 53-64
        • Bonsnes RW
        • Taussky HH
        The colorimetric determination of creatinine by the Jaffe reaction.
        J Biol Chem. 1945; 158: 581-591
        • Stork JE
        • Dunn MJ
        Hemodynamic roles of thromboxane A2 and prostaglandin E2 in glomerulonephritis.
        J Pharmacol Exp Ther. 1985; 233: 672-678
        • Schlondorff D
        • Neuwirth R
        Platelet-activating factor and the kidney.
        Am J Physiol. 1986; 251: F1-F11
        • Shaw JO
        • Klusick SJ
        • Hanahan DJ
        Activation of rabbit platelet phospholipase and thromboxane synthesis by 1-0-hexadecyl-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet activating factor).
        Biochim Biophys Acta. 1981; 663: 222-229
        • Neuwirth R
        • Singhal P
        • Satriano JA
        • Braquet P
        • Shen TY
        • Schlondorff D
        Stimulation of PGE2 synthesis by platelet-activating factor (PAF) in mesangial cells is inhibited by BN52021 and kadsurenone [Abstract].
        in: Sixth International Conference on Prostaglandins and Related Compounds, Florence, Italy, 1986 Raven Press, New York1986: 320
        • Stork JE
        • Shen TY
        • Dunn MJ
        Stimulation of prostaglandin E2 and thromboxane B2 production in cultured rat mesangial cells by platelet activating factor: inhibition by a specific receptor antagonist [Abstract].
        Kidney Int. 1985; 27: 267
        • Scharschmidt LA
        • Lianos E
        • Dunn MJ
        Arachidonate metabolites and the control of glomerular function.
        in: 3rd ed. Fed Proc. 42. 1983: 3058-3063
        • Jackson EK
        • Heidemann HT
        • Branch RA
        • Gerkens JF
        Low dose intrarenal infusions of PGE2, PGI2, and 6-keto-PGF vasodilate the in vivo rat kidney.
        Circ Res. 1982; 51: 67-72
        • Schor N
        • Ichikawa I
        • Brenner BM
        Mechanisms of action of various hormones and vasoactive substances on glomerular ultrafiltration in the rat.
        Kidney Int. 1981; 20: 442-451
        • Clive DM
        • Stoff JS
        Renal syndromes associated with nonsteroidal antiinflammatory drugs.
        N Engl J Med. 1984; 310: 563-572
        • Lianos EA
        • Noble B
        Glomerular arachidonate-5 lipoxygenation in active (A) and Passive (P) Heymann nephritis [Abstract].
        Kidney Int. 1986; 31: 277
        • Sraer J
        • Rigaud M
        • Bens M
        • Rabinovitch H
        • Ardaillou R
        Metabolism of arachidonic acid via the lipoxygenase pathway in human and murine glomeruli.
        J Biol Chem. 1983; 258: 4325-4330
        • Jim K
        • Hassid A
        • Sun F
        • Dunn MJ
        Lipoxygenase activity in rat kidney glomeruli, glomerular epithelial cells and cortical tubules.
        J Biol Chem. 1982; 257: 10294-10299
        • Badr KF
        • Baylis C
        • Pfeffer JM
        • et al.
        Renal and systemic hemodynamic responses to intravenous infusion of leukotriene C4 in the rat.
        Circ Res. 1984; 54: 492-499
        • Filep J
        • Rigter B
        • Frolich JC
        Vascular and renal effects of leukotriene C4 in conscious rats.
        Am J Physiol. 1985; 249: F739-F744
        • Badr KF
        • Brenner BM
        • Wasserman M
        • Ichikawa I
        Evidence for local glomerular actions of leukotriene D4 (LTD4) [Abstract].
        Kidney Int. 1986; 29: 328
        • Lianos EA
        • Andres GA
        • Dunn MJ
        Glomerular prostaglandin ad thromboxane synthesis in rat nephrotoxic serum nephritis. Effects on renal hemodynamics.
        J Clin Invest. 1983; 72: 1439-1448
        • Thomson NM
        • Holdsworth SR
        • Glasgow EF
        • Atkins RC
        The macrophage in the development of experimental crescentic glomerulonephritis. Studies using tissue culture and electron microscopy.
        Am J Pathol. 1979; 94: 223-240
        • Delaini F
        • Tagliaferri M
        • Macconi D
        • Lupini C
        • Perico N
        • Remuzzi G
        Platelet activating factor (PAF) as a mediator of proteinuria in isolated perfused kidney (IPK) [Abstract].
        in: Tenth International Congress of Nephrology, London, 1987 The Alden Press, Oxford1987: 263
        • Perico N
        • Delaini F
        • Tagliaferri M
        • et al.
        The effect of platelet-activating factor and its specific receptor antagonist on glomerular permeability to proteins in isolated perfused rat kidney.
        Lab Invest. 1988; 58: 163-171
        • Hébert RL
        • Sirois P
        • Braquet P
        • Plante GE
        Hemodynamic effects of PAF-acether on the dog kidney.
        Prostaglandins Leukotrienes Med. 1987; 26: 189-202
        • Scherf H
        • Nies AS
        • Schwertschlag U
        • Hughes M
        • Gerber JG
        Hemodynamic effects of platelet activating factor in the dog kidney in vivo.
        Hypertension. 1986; 8: 737-742
        • Sraer J
        • Foidart J
        • Chansel D
        • Mahieu P
        • Kouznetsov B
        • Ardaillou R
        Prostaglandin synthesis by mesangial and epithelial glomerular cultured cells.
        FEBS Lett. 1979; 104: 420-424